Berkeley Lights announced today that Novartis is implementing BLI’s Beacon platform to help accelerate their antibody discovery workflow.
| |
| [16-January-2018] |
| EMERYVILLE, Calif., Jan. 16, 2018 /PRNewswire/ -- Berkeley Lights, a company dedicated to bringing to market transformational platforms for biopharmaceutical processes, announced today that Novartis is implementing BLI’s Beacon platform to help accelerate their antibody discovery workflow. Novartis was an early adopter of the BLI technology and the results from this early work has culminated in the adoption of the Beacon platform. The Beacon platform is capable of screening thousands of antibody producing cells in 48 hours. Cell characterizations are performed through a variety of serial or multiplex fluorescence assays to determine antigen-specificity for both soluble and membrane bound targets, relative binding affinity, and functional response. Individual cells with the desired characteristics are selected and exported for further manipulation. All of these functions are automated and are performed with minimal hands-on time by scientists. Both the time compression and automation of discovery workflows enable faster iteration and innovation to develop more valuable targets. “Through automation and precision, Berkeley Lights is providing the speed and versatility that is accelerating antibody discovery,” said Eric Hobbs, PhD, CEO at BLI. “We look forward to expanding our relationship with Novartis and continuing to deliver high value solutions.” To learn more about the Beacon Antibody Discovery Workflow, visit: https://www.berkeleylights.com/beacon-applications/antibody-discovery/ About Berkeley Lights: ?Berkeley Lights, Inc. (BLI) develops and commercializes platforms on which many bio-pharmaceutical, genomic, and cellular therapy applications will run. BLI launched its first commercial platform, the Beacon®*, in December 2016. The Beacon platform is ideally suited for cell line development and direct B-cell (plasma and memory cells) antibody discovery workflows. The flexibility of the Beacon platform allows users to automate biological processes and BLI is continuously developing new applications to align with its partners’ requirements. BLI’s technologies make it possible for customers to accelerate learning and dramatically improve workflows. * For Research Use Only. Not for use in diagnostic procedures. For more information, visit http://www.berkeleylights.com/.
View original content with multimedia:http://www.prnewswire.com/news-releases/another-large-pharma-implements-berkeley-lights-beacon-optofluidic-platform-for-accelerating-antibody-discovery-300582808.html SOURCE Berkeley Lights, Inc. |
